Autoimmune Disease and the Mistaken Self Reference

April 25, 2005 - Natural Products Industry INSIDE
Autoimmune Disease and the Mistaken Self References

1. Ebers GC et al. Vitamin D intake and incidence of multiple sclerosis.Neurol. 63, 5:939, 2004. www.neurology.org

2. Hayes, CE. Vitamin D:a natural inhibitor of multiple sclerosis. ProcNutr Soc. 59, 4:531-5, 2000. www.cabi-publishing.org/journals/pns

3. Chaudhuri A. Why we should offer routine vitamin D supplementation inpregnancy and childhood to prevent multiple sclerosis. Med Hypotheses.64, 3:608-18, 2005. www.harcourt-international.com/journals/mehy

4. ibid.

5. Johnson S. The possible role of gradual accumulation of copper,cadmium, lead and iron and gradual depletion of zinc, magnesium, selenium,vitamins B2, B6, D and E and essential fatty acids in multiple sclerosis. MedHypotheses. 55, 3:239-41, 2000. www.harcourt-international.com/journals/mehy

6. Yasui M and Ota K. Experimental and clinical studies on dysregulationof magnesium metabolism and aetiopathogenesis of multiple sclerosis. MagnesRes. 5, 4:295-302, 1992.

7. Besler HT et al. Serum levels of antioxidant vitamins and lipidperoxidation in multiple sclerosis. Nutr Neurosci. 5, 3:215-20, 2002. www.tandf.co.uk/journals/titles/1028415x.html

8. Hawkins SA et al. A double blind controlled trial of long chain n-3polyunsaturated fatty acids in the treatment of multiple sclerosis. JNeurol Neurosurg Psychiatry. 52, 1:18-22, 1989.

9. Bates D. Dietary lipids and multiple sclerosis. Ups J Med Sci.Supp 48:173-87, 1990.

10. Gallai V et al. Cytokine secretion and eicosanoid production in theperipheral blood mononuclear cells of MS patients undergoing dietarysupplementation with n-3 polyunsaturated fatty acids. J Neuroimmunol.56, 2:143-53, 1995.

11. Nordvik I et al. Effect of dietary advice and n-3 supplementation innewly diagnosed MS patients. Actol Neurol Scand. 102, 3:143-9, 2000.

12. Nie ZG et al. [Effects of ginkgolide B on lipopolysaccharide-inducedTNFalpha production in mouse peritoneal macrophages and NF-kappaB activation inrat pleural polymorphonuclear leukocytes.] Yao Xue Xue Bao. 39,6:415-8, 2004.

13. Howat DW et al. An investigation into the possible involvement ofplatelet activating factor in experimental allergic encephalomyelitis in rats.Agents Actions. 31:43-6, 1990.

14. Brochet B et al. Pilot study of Ginkgolide B, a PAF-acether specificinhibitor in the treatment of acute outbreaks of multiple sclerosis. RevNeuro. 148:299301, 1992.

15. Guinot p et al. Double blind placebo controlled multicentre study ofginkgolide B in treatment of acute exacerbations of multiple sclerosis. TheGinkgolide Study Group in multiple sclerosis. J Neurol NeurosurgPsychiatry. 58, 3:360-2, 1995.

16. American Academy of Neurology Annual Meeting, April 13-20, San Diego. www.aan.com

17. Korwin-Piotrowska T et al. Experience of Padma 28 in multiplesclerosis. Phytother Res. 6:1336, 1992. www.interscience.wiley.com/jpages/0951-418X

18. Dignam R et al. The effect of cranberry juice on urinary tractinfection rates in a long-term care facility. Annals Long-Term Care.6, 5), 1998. www.mmhc.com/altc/displayArticle.cfm?articleID=altcac70

19. Stothers L. A randomized trial to evaluate effectiveness and costeffectiveness of naturopathic cranberry products as prophylaxis against urinarytract infection in women. Can J Urol. 9, 3:1558-62, 2002.

20. Jepson RG et al. Cranberries for preventing urinary tract infections.Cochrane Database Syst Rev. , 2:CD001321, 2004. www.cochrane.org

21. Lynch DM. Cranberry for prevention of urinary tract infections. AmFam Physician. 70, 11:2175-7, 2004. www.aafp.org/afp

22. Duffy EM et al. The clinical effect of dietary supplementation withomega-3 fish oils and/or copper in systemic lupus erythematosus. JRheumatol. 31, 8:1551-6, 2004. www.jrheum.com

23. Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoicacids in the management of systemic lupus erythematosus and its relationship tothe cytokine network. Prostagland Leukotr Essent Fatty Acids. 51,3:207-13, 1994. www.harcourt-international.com/journals/plef

24. Leiba A et al. Diet and lupus. Lupus. 10, 3:246-8, 2001.

25. Das UN. Hypothesis: can glucose-insulin-potassium regimen incombination with polyunsaturated fatty acids suppress lupus and otherinflammatory conditions? Prostagland Leukotr Essent Fatty Acids. 65,2:109-13, 2001. www.harcourt-international.com/journals/plef

26. Lawrence RA et al. Inhibition of intracellular peroxides and apoptosisof lymphocytes in lupus-prone B/W mice by dietary n-6 and n-3 lipids withcalorie restriction. J Clin Immunol. 22, 4:206-19, 2002. www.kluweronline.com/issn/0271-9142/current

27. Sun D et al. Age associated alterations in co-stimulatory and adhesionmolecule expression in lupus-prone mice are attenuated by food restriction withn-6 and n-3 fatty acids. J Clin Immunol. 24, 5:471-80, 2004. www.kluweronline.com/issn/0271-9142/current

28. Jolly CA and Fernandes G. Diet modulates Th-1 and Th-2 cytokineproduction in the peripheral blood of lupus-prone mice. J Clin Immunol.19, 3:172-8, 1999. www.kluweronline.com/issn/0271-9142/current

29. Chu WC and Venkatraman JT. Effects of dietary omega-3 and omega-6lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodiesin a mouse model for rheumatoid arthritis. J Am Coll Nutr. 18,6:602-13, 1999. www.am-coll-nutr.org/jacn/jacn.htm

30. Reifen R et al. Dietary polyunsaturated fatty acids decreaseanti-dsDNA and anti-cardiolipin antibodies production in idiotype induced mousemodel of systemic lupus erythematosus. Lupus. 7, 3:192-7, 1998.

31. Krishnan A et al. Effect of dietary n-3 and n-6 oils with and withoutfood restriction on activity of antioxidant enzymes and lipid peroxidation inlivers of cyclophosphamide treated autoimmune-prone NZB/W female mice. JAm Coll Nutr. 22, 5:388-99, 2003. www.am-coll-nutr.org/jacn/jacn.htm

32. Bito T et al. Pine bark extract pycnogenol downregulatesIFN-gamma-induced adhesion of T cells to human keratinocytes by inhibitinginducible ICAM-1 expression. Free Rad Biol Med. 28, 2:219-27, 2000. www.elsevier.com/locate/freeradbiomed

33. Stefanescu M et al. Pycnogenol efficacy in the treatment of systemiclupus erythematosus patients. Phytother Res. 15, 8:698-704, 2001. www.interscience.wiley.com/jpages/0951-418X

34. Qiu D and Kao P. Immunosuppressive and anti-inflammatory mechanisms oftriptolide, the principal active diterpenoid from the Chinese medicinal herbTripterygium wilfordii Hook. f. Drugs R D. 4, 1:1-18, 2003.

35. Chang Dm et al. The effects of traditional antirheumatic herbalmedicines on immune response cells. J Rheumatol. 24, 3:436-41, 1997. www.jrheum.com

36. Luk JM et al. Suppression of cytokine production and cell adhesionmolecule expression in human monocytic cell line THP-1 by Tripterygium wilfordiipolysaccharide moiety. Life Sci. 67, 2:155-63, 2000. www.sciencedirect.com/science/journal/00243205

37. Kao NL et al. Resolution of severe lupus nephritis associated withTripterygium wilfordii hook F ingestion. Arthritis Rheumatism. 36,12:1751-2, 1993. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746

38. Auborn KJ et al. Lifespan is prolonged in autoimmune-prone , NZB/NZW)F1 mice fed a diet supplemented with indole-3-carbinol. J Nutr. 133,11:3610-3, 2003. www.nutrition.org.

39. Comstock GW et al. Serum concentrations of alpha tocopherol, betacarotene, and retinol preceding the diagnosis of rheumatoid arthritis andsystemic lupus erythematosus. Ann Rheum Dis. 56, 5:323-5, 1997. www.annrheumdis.com.

40. Bae DC et al. Impaired antioxidant status and decreased dietary intakeof antioxidants in patients with systemic lupus erythematosus. RheumatolInt. 22, 6:238-43, 2002.

41. Weismann BJ and Weiser H. Effects of antioxidant vitamins C, E, andbeta-carotene on immune functions in MRL/lpr mice and rats Ann N Y AcadSci. 669:390-2, 1992. www.nyas.org/publications/annals/

42. Tam LS et al. Effects of vitamins C and E on oxidative stress markersand endothelial function in patients with systemic lupus erythematosus: a doubleblind, placebo controlled pilot study. J Rheumatol. 32, 2:275-82,2005. www.jrheum.com

43. Brown AC. Lupus eryhtematosus and nutrition: a review of theliterature. J Ren Nutr. 10, 4:170-83, 2000. www.jrnjournal.org

44. Weimann BJ and Hermann D. Inhibition of autoimmune deterioration inMRL/lpr mice by vitamin E. Int J Vitam Nutr Res. 69, 4:255-61, 1999.

45. Minami Y et al. Diet and systemic lupus erythematosus:a 4 yearprospective study of Japanese patients. J Rheumatol. 30, 4:747-54,2003. www.jrheum.com

46. Yilmaz A et al. Trace elements and some extracellular antioxidantproteins levels in serum of patients with systemic lupus erythematosus. ClinRheumatol. Epub. Dec. 4, 2004. http://link.springer.de/link/service/journals/10067

47. Chang Dm et al. Dehydroepiandrosterone treatment of women withmild-to-moderate systemic lupus erythematosus: a multicenter randomized,double-blind, placebo-controlled trial. Arthritis Rheumatism. 46,11:2924-7, 2002. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746

48. Chu SJ et al. Dehydroepiandrosterone suppresses interleukin 10synthesis in women with systemic lupus erythematosus. Ann Rheum Dis.63, 12)1623-6, 2004. www.annrheumdis.com.

49. Hartkamp A et al. The effect of dehydroepiandrosterone on lumbar spinebone mineral density in patients with quiescent systemic lupus erythematosus.Arthritis Rheumatism. 50, 11:3591-5, 2004. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746

50. Sen D and Keen RW. Osteoporosis in systemic lupus erythematosus:prevention and treatment. Lupus. 10, 3:227-32, 2001.

51. Karatas F et al. Antioxidant status & lipid peroxidation inpatients with rheumatoid arthritis. Indian J Med Res. 118:178-81,2003.

52. Paredes S et al. Antioxidant vitamins and lipid peroxidation inpatients with rheumatoid arthritis: association with inflammatory markers. JRheumatol. 29, 11:2271-7, 2002. www.jrheum.com

53. Hagfors L et al. "Antioxidant intake, plasma antioxidants andoxidative stress in a randomized, controlled, parallel, Mediterranean dietaryintervention study on patients with rheumatoid arthritis." Nutr J.2, 1:5, 2003. www.nutritionj.com

54. Bae SC et al. "Inadequate antioxidant nutrient intake and alteredplasma antioxidant status of rheumatoid arthritis patients." J Am CollNutr. 22, 4:311-5, 2003. www.am-coll-nutr.org/jacn/jacn.htm

55. Cerhan JR et al. "Antioxidant micronutrients and risk of rheumatoidarthritis in a cohort of older women." Am J Epidemiol. 157,4:345-54, 2003. www.aje.oupjournals.org

56. Merlino LA et al. Vitamin D intake is inversely associated withrheumatoid arthritis:results from the Iowa Women's Health Study. ArthritisRheumatism. 50, 1:72-7, 2004. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746

57. Cerhan JR et al. Antioxidant micronutrients and risk of rheumatoidarthritis in a cohort of older women. Am J Epidemiol. 157, 4:345-54,2003. www.aje.oupjournals.org

58. Kiziltunic A et al. Carnitine and antioxidants levels in patients withrheumatoid arthritis. Scand J Rheumatol. 27, 6:441-5, 1998.

59. DeLuca P et al. Effects of gamma-linolenic acid on interleukin-1 betaand tumor necrosis factor-alpha secretion by stimulated human peripheral bloodmonocytes: studies in vitro and in vivo. J Investig Med. 47, 5:246-50,1999.

60. Furse RK et al. Oral administration of gamma linolenic acid, anunsaturated fatty acid with anti-inflammatory properties, modulatesinterleukin-1beta production by human monocytes. J Clin Immunol. 22,2:83-91, 2002. www.kluweronline.com/issn/0271-9142/current

61. Brzeski M et al. Evening primrose oil in patients with rheumatoidarthritis and side-effects of non-steroidal anti-inflammatory drugs. Br JRheumatol. 30, 5:370-2, 1991.

62. Laposata m et al. Alteration of the cellular fatty acid profile andthe production of eicosanoids in human monocytes by gamma-linolenic acid. ArthritisRheumatism. 33, 10:1526-33, 1990. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746

63. Watson J et al. Cytokine and prostaglandin production by monocytes ofvolunteers and rheumatoid arthritis patients treated with dietary supplements ofblackcurrant seed oil. Br J Rheumatol. 32, 12:1055-8, 1993.

64. Boyce EG et al. Treatment of rheumatoid arthritis with blackcurrantseed oil. Br J Rheumatol. 33, 9:847-52, 1994.

65. Nordstrom DC et al. Alpha-linolenic acid in the treatment ofrheumatoid arthritis. A double-blind, placebo-controlled and randomized study:flaxseed vs. safflower seed. Rheumatol Int. 14, 6:231-4, 1995.

66. Adam O. Dietary fatty acids and immune reactions in synovial tissue.Eur J Med Res. 8, 8:381-7, 2003.

67. Venkatraman J and Meksawan K. Effects of dietary omega3 and omega6lipids and vitamin E on chemokine levels in autoimmune-prone MRL/MpJ-lpr/lprmice. J Nutr Biochem. 13, 8:479, 2002. www.elsevier.com/locate/jnutbio

68. James MJ et al. Dietary n-3 fats as adjunctive therapy in a prototypicinflammatory disease:issues and obstacles for use in rheumatoid arthritis. ProstaglandLeukotr Essent Fatty Acids. 68, 6:399-405, 2003. www.harcourt-international.com/journals/plef

69. Cleland LG et al. The role of fish oils in the treatment of rheumatoidarthritis. Drugs. 63, 9:845-53, 2003.

70. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmunediseases. J Am Coll Nutr. 21, 6:495-505, 2002. www.am-coll-nutr.org/jacn/jacn.htm.

71. Kless T et el. Anti-inflammatory effects of a low arachidonic aciddiet and fish oil in patients with rheumatoid arthritis. Rheumatol Int.23, 1:27-36, 2003.

72. Berbert AA et al. Supplementation of fish oil and olive oil inpatients with rheumatoid arthritis. Nutrition. 21, 2:131-6, 2005. www.journals.elsevierhealth.com/periodicals/nut

73. Gruenwald J et al. Efficacy and tolerability of a combination ofLyprinol and high concentrations of EPA and DHA in inflammatory rheumatoiddisorders. Adv Ther. 21, 3:197-201, 2004.

74. Halpern GM. Anti-inflammatory effects of a stabilized lipid extract ofPerna canaliculus, Lyprinol. Allerg Immunol. 32, 7:272-8, 2000.

75. Bagchi D et al. Effects of orally administered undenatured type IIcollagen against arthritic inflammatory diseases:a mechanistic exploration. IntJ Clin Pharmacol Res. 22:101-10, 2002.

76. Trentham DE et al. Effects of oral administration of type II collagenon rheumatoid arthritis. Science. 261, 5129:1727-30, 1993. www.sciencemag.org

77. Ausar SF et al. Treatment of rheumatoid arthritis by oraladministration of bovine tracheal type II collagen. Rheumatol Int. 20,4:138-44, 2001.

78. Abdullaeva GK and Shakimova BS. [An evaluation of the efficacy oftreating rheumatoid arthritis with preparations for local use] Revmatologiia(Mosk). 4:35-9, 1985.

79. Anikina NV et al. [The effect of dimethyl sulfoxide on thethromboelastographic indices and the microcirculation in patients with rheumaticdiseases] Ter Arkh. 61, 12:106-9, 1989.

80. Srivastava KC and Mustafa T. Ginger , Zingiber officinale) andrheumatic disorders. Med Hypotheses. 29, 1:25-8, 1989. www.harcourt-international.com/journals/mehy

81. Srivastava KC and Mustafa T. Ginger , Zingiber officinale) inrheumatic and muscoskeletal disorders. Med Hypotheses. 39, 4:342-8,1992. www.harcourt-international.com/journals/mehy

82. Ammon HP. [Boswellic acids , components of frankincense) as the activeprinciple in treatment of chronic inflammatory diseases] Wien MedWochenschr. 152:373-8, 2002.

83. Sharma JN. Comparison of the anti-inflammatory activity of Commiphoramukul , an indigenous drug) with those of phenylbutazone and ibuprofen inexperimental arthritis induced by mycobacterial adjuvant. Arzneimittelforschung.27, 7:1455-7, 1977.

84. Mur E et al. Randomized double blind trial of an extract from thepentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment ofrheumatoid arthritis. J Rheumatol. 29, 4:678-81, 2002. www.jrheum.com

85. Zhang XJ et al. Anti-inflammatory actions of cats claw: the role ofNF-kappaB. Aliment Pharmacol Ther. 12, 12:1279-89, 1998.

86. Behnke B et al. Effects of the antirheumatic remedy hox alpha--a newstinging nettle leaf extract--on matrix metalloproteinases in human chondrocytesin vitro. Histol Histopathol. 17, 2:477-85, 2002.

87. Broer J and Behnke B. Immunosuppressant effect of IDS 30, a stingingnettle leaf extract, on myeloid dendritic cells in vitro. J Rheumatol.29, 4:656-8, 2002. www.jrheum.com

88. Baz K et al. Oxidant / antioxidant status in patients with psoriasis.Yonsei Med J. 44, 6:987-90, 2003.

89. Yildirim M et al. The role of oxidants and antioxidants in psoriasis.J Eur Acad Dermatol Venereol. 17, 1:34-6, 2003.

90.Van Zander J and Orlow SJ. Efficacy and safety of oral retinoids inpsoriasis. Expert Opin Drug Saf. 4, 1:129-38, 2005. www.ashley-pub.com

91. Serwin AB et al. Selenium status in psoriasis and its relations to theduration and severity of the disease. Nutrition. 19, 4:301-4, 2003. www.journals.elsevierhealth.com/periodicals/nut

92. Ben-Shabat S et al. Vitamin D3-based conjugates for topical treatmentof psoriasis:synthesis, antiproliferative activity, and cutaneous penetrationstudies. Pharm Res. 22, 1:50-7, 2005.

93. Mayser p et al. Omega-3 fatty acid-based lipid infusion in patientswith chronic plaque psoriasis: results of a double-blind, randomized,placebo-controlled, multicenter trial. J Acad Dermatol. 38, 4:539-47,1998.

94. Gupta AK et al. Double-blind, placebo-controlled study to evaluate theefficacy of fish oil and low-dose UVB in the treatment of psoriasis. Br JDermatol. 120, 6:801-7, 1989.

95. Syed TA et al. Management of psoriasis with Aloe vera extract in ahydrophilic cream:a placebo-controlled, double-blind study. Trop Med IntHealth. 1, 4:505-9, 1996.

96. Mantle D et al. Adverse and beneficial effects of plant extracts onskin and skin disorders. Adverse Drug React Toxicol Rev. 20, 2:89-103,2001.

97. Zhang WY and Li Wan Po A. The effectiveness of topically appliedcapsaicin. A meta-analysis. Eur J Clin Pharmacol. 46, 6:517-22, 1994.

98. Ellis CN et al. A double-blind evaluation of topical capsaicin inpruritic psoriasis. J Am Acad Dermatol. 29, 3:438-42, 1993. www.eblue.org

99. Reimann S et al. [Topical Administration of capsaicin in dermatologyfor treatment of itching and pain.] Hautarzt. 51, 3:164-72, 2000.

100. Krogstad AL et al. Capsaicin treatment induces histamine release andperfusion changes in psoriatic skin. Br J Dermatol. 141, 1:87-93,1999.

101. Bito T et al. Pine bark extract pycnogenol downregulatesIFN-gamma-induced adhesion of T cells to human keratinocytes by inhibitinginducible ICAM-1 expression. Free Rad Biol Med. 28, 2:219-27, 2000. www.elsevier.com/locate/freeradbiomed

102. Han MK. Epigallocatechin gallate, a constituent of green tea,suppresses cytokine-induced pancreatic beta-cell damage. Exp Mol Med.35, 2:136-9, 2003.

103. Giullietti A et al. Vitamin D deficiency in early life acceleratesType 1 diabetes in non-obese diabetic mice. Diabetologia. 47,3:451-62, 2004.

104. Yanardag R et al. "Effects of vanadyl sulfate on kidney inexperimental diabetes." Biol Trace Elem Res. 95, 1:73-86, 2003. www.humanapress.com.

105. Krishna Mohan I and Das UN. Prevention of chemically induced diabetesmellitus in experimental animals by polyunsaturated fatty acids. Nutrition.17, 2:126-51, 2001. www.journals.elsevierhealth.com/periodicals/nut

106. Stene LC et al. Use of cod liver oil during the first year of life isassociated with lower risk of childhood-onset type 1 diabetes: a large,population-based, case-control study. Am J Clin Nutr. 78, 6:1128-34,2003. www.ajcn.org

107. Ruiz C et al. Selenium, zinc and copper in plasma of patients withtype 1 diabetes mellitus in different metabolic control states. J TraceElem Med Biol. 12, 2:91-5, 1998.

108. Osterode W et al. Nutritional antioxidants, red cell membranefluidity and blood viscosity in type 1 , insulin dependent) diabetes mellitus.Diabet Med. 13, 12:1044-50, 1996.

109. Ergas D et al. N-3 fatty acids and the immune system in autoimmunity.Isr Med Assoc J. 4, 1:34-8, 2002.

110. Belluzzi A et al. Effect of enteric-coated fish oil preparation onrelapses in Crohns disease. N Engl J Med. 334, 24:1557-60, 1996. http://content.nejm.org

111. Trebble TM et al. Fish oil and antioxidants alter the composition andfunction of circulating mononuclear cells in Crohn disease. Am J Clin Nutr.80, 5:1137-44, 2004. www.ajcn.org

112. Gupta I et al. Effects of gum resin of Boswellia serrata in patientswith chronic colitis. Planta Med. 67, 5:391-5, 2001.

113. Gerhardt H et al. [Therapy of active Crohn disease with Boswelliaserrate extract H 15.] Z Gastroenterol. 39, 1:11-7, 2001.

114. Ma TY et al. TNF-alpha-induced increase in intestinal epithelialtight junction permeability requires NF-kappa B activation. Am J PhysiolGastrointest Liver Physiol. 286, 3:G367-76, 2004.

115. Zhou H and Mineshita S. The effect of berberine chloride inexperimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther.294:822-829, 2000.

116. Andus T et al. Patients with refractory Crohn's disease or ulcerativecolitis respond to dehydroepiandrosterone: a pilot study. AlimentPharmacol Ther. 17, 3:409-14, 2003.

117. Sartor RB. Therapeutic manipulation of the enteric microflora ininflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology.126, 6:1620-33, 2004. www.gastrojournal.org

118. Borreul N et al. Increased mucosal tumur necrosis factor alphaproduction in Crohns disease can be downregulated ex vivo by probioticbacteria. Gut. 51:659-664, 2002. http://gut.bmjjournals.com

119. Kanauchi O et al. The beneficial effects of microflora, especiallyobligate anaerobes, and their products on the colonic environment ininflammatory bowel disease. Curr Pharm Des. 11, 8:1047-53, 2005.

120. Boudeau J et al. Inhibitory effect of probiotic Escherichia colistrain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells byadherent-invasive E. coli strains isolated from patients with Crohn's disease.Aliment Pharmacol Ther. 18, 1:45-56, 2003.

121. Malchow HA. Crohn's disease and Escherichia coli. A new approach intherapy to maintain remission of colonic Crohn's disease? J ClinGastroenterol. 25, 4:653-8., 1997.

122. Malin M et al. Promotion of IgA immune response in patients withCrohns disease by oral bacteriotherapy with Lactobacillus GG. Ann NutrMetab. 40:137-145, 1996. www.karger.com/anm

123. Gupta P et al. Is Lactobacillus GG helpful in children with Crohnsdisease? Results of a preliminary, open-label study. J PediatrGastroenterol Nutr. 31:453-457, 2000.

124. Ott SJ et al. Reduction in diversity of the colonic mucosa associatedbacterial microflora in patients with active inflammatory bowel disease. Gut.53, 5:685-93, 2004. www.gut.bmjjournals.com.

125. Horie H et al. "Effects of intestinal bacteria on the developmentof colonic neoplasm: an experimental study." Eur J Cancer Prev. 8,3:237-45, 1999.

126. Plein K and Hotz J. Therapeutic effects of Saccharomyces boulardiion mild residual symptoms in a stable phase of Crohns disease with specialrespect to chronic diarrhea a pilot study. Z Gastroenterol.31:129-34, 1993.

127. Guslandi M et al. Saccharomyces boulardii in maintenancetreatment of Crohns disease. Dig Dis Sci. 45:1462-64, 2000. www.kluweronline.com/issn/0163-2116/current

128. Siffledeen JS et al. The frequency of vitamin D deficiency in adultswith Crohn's disease. Can J Gastroenterol. 17, 8:473-8, 2003.

129. Fedorak R et al. Randomized trial of etidronate plus calcium andvitamin D for treatment of low bone mineral density in Crohn's disease. ClinGastroenterol Hepatol. 3, 2:122-32, 2005.

130. Rannem T et al. Selenium depletion in patients with gastrointestinaldiseases:are there any predictive factors? Scand J Gastroenterol. 33,10:1057-61, 1998.

131. Hodges P et al. Vitamin and iron intake in patients with Crohnsdisease. J Am Diet Assoc. 84, 1:52-8, 1984. www.adajournal.org

132. Jahnsen J et al. Vitamin D status, parathyroid hormone and bonemineral density in patients with inflammatory bowel disease. Scand JGastroenterol. 37, 2:192-9, 2002.

133. Bousvaros A et al. Vitamins A and E serum levels in children andyoung adults with inflammatory bowel disease: effect of disease activity. JPediatr Gastroenterol Nutr. 26, 2:129-35, 1998.

134. Gasche C et al. Iron, anaemia and inflammatory bowel disease. Gut.53, 8:1190-7, 2004. www.gut.bmjjournals.com.

135. Chowers Y et al. Increased levels of homocysteine in patients withCrohn's disease are related to folate levels. Am J Gastroenterol.95:3498-3502, 2000. www.amjgastro.com

136. Wahner-Roedler DL et al. Use of complementary and alternative medicaltherapies by patients referred to a fibromyalgia treatment program at a tertiarycare center. Mayo Clin Proc. 80, 1:55-60, 2005. www.mayo.edu/proceedings

137. OMalley PG et al. Treatment of fibromyalgia with antidepressants:a meta-analysis. J Gen Intern Med. 15, 9:659-66, 2000.

138. Jacobsen S et al. Oral S-adenosylmethionine in primary fibromyalgia.Double-blind clinical evaluation. Scand J Rheumatol. 20, 4:294-302,1991.

139. Birdsall TC. 5-Hydroxytryptophan:a clinically-effective serotoninprecursor. Altern Med Rev. 3, 4:271-80, 1998. www.thorne.com/altmedrev

140. Juhl JH. Fibromyalgia and the serotonin pathway. Altern Med Rev.3, 5:367-75, 1998. www.thorne.com/altmedrev

141. Nicolodi M and Sicuteri F. Fibromyalgia and migraine, two faces ofthe same mechanism. Serotonin as the common clue for pathogenesis and therapy.Adv Exp Med Biol. 398:373-9, 1996.

142. Puttini PS and Caruso I. Primary fibromyalgia syndrome and5-hydroxy-L-tryptophan:a 90-day open study. J Int Med Res. 20,2:182-9, 1992. www.jimronline.net

143. Citera G et al. The effect of melatonin in patients withfibromyalgia: a pilot study. Clin Rheumatol. 19, 1:9-13, 2000. http://link.springer.de/link/service/journals/10067

144. Regland B et al. Increased concentrations of homocysteine in thecerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome.Scand J Rheumatol. 26, 4:301-7, 1997.

145. Lister RE. An open, pilot study to evaluate the potential benefits ofcoenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. JInt Med Res. 30, 2:195-9, 2002. www.jimronline.net

146. Russell IJ et al. Treatment of fibromyalgia syndrome with SuperMalic: a randomized, double blind, placebo controlled, crossover pilot study.J Rheumatol. 22, 5:953-8, 1995. www.jrheum.com

147. Tanabe k et al. Erythrocyte magnesium and prostaglandin dynamics inchronic sleep deprivation. Clin Cardiol. 20, 3:265-8, 1997.

148. Weglicki WB and Phillips TM. Pathobiology of magnesium deficiency: acytokine/neurogenic inflammation hypothesis. Am J Physiol. 263, 3 Pt2:R734-7, 1992.

149. Eisinger J et al. Selenium and magnesium status in fibromyalgia. MagnesRes. 7, 3-4:285-8, 1994.

150. Park JH et al. Use of P-31 magnetic resonance spectroscopy to detectmetabolic abnormalities in muscles of patients with fibromyalgia. ArthritisRheumatism. 41, 3:406-13, 1998. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746

151. Gebhart B and Jorgenson JA. Benefit of ribose in a patient withfibromyalgia. Pharmacother. 24, 11:1646-8, 2004.

152. Sinclair C et al. Muscle carnitine in hypo- and hyperthyroidism. MuscleNerve. [Epub ahead of print] Mar 31, 2005.

153. Benvenga S et al. Usefulness of L-carnitine, a naturally occurringperipheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism:a randomized, double-blind, placebo-controlled clinical trial. J ClinEndocrinol Metab. 86, 8:3579-94, 2001. http://jcem.endojournals.org

154. Gadeleta MN et al. Acetyl-L-carnitine increases cytochrome oxidasesubunit I mRNA content in hypothyroid rat liver. FEBS Lett. 277,1-2:191-3, 1990. www.elsevier.com/febs//show

155. Knudsen N et al. Large differences in incidences of overt hyper- andhypothyroidism associated with a small difference in iodine intake: aprospective comparative register-based population survey. J ClinEndocrinol Metab. 87, 10:4462-9, 2002. http://jcem.endojournals.org

156. Sarandol E et al. Oxidative stress and serum paraoxonase activity inexperimental hypothyroidism: effect of vitamin E supplementation. CellBiochem Funct. 23, 1:1-8, 2005.

157. Hawkes WC and Keim NL. Dietary selenium intake modulates thyroidhormone and energy metabolism in men. J Nutr. 133, 11:3443-8, 2003. www.nutrition.org

158. Baskin SI et al. Correlation of platelet taurine levels with thyroidfunction. J Endocrinol Invest. 2, 3:245-9, 1979.

159. Tas S et al. The effect of taurine supplementation on oxidativestress in experimental hypothyroidism. Cell Biochem Funct. Dec 22,2004. [Epub ahead of print]

160. Seymen HO et al. Iron supplementation in experimentalhyperthyroidism:effects on oxidative stress in skeletal muscle tissue. YonseiMed J. 45, 3:413-8, 2004.

161. Goswami UC and Choudhury S. The status of retinoids in womensuffering from hyper- and hypothyroidism: interrelationship between vitamin A,beta-carotene and thyroid hormones. Int J Vitam Nutr Res. 69, 2:132-5,1999.

162. Pallet V et al. Retinoic acid differentially modulatestriiodothyronine and retinoic acid receptors in rat liver according to thyroidstatus. Eur J Endocrinol. 131, 4:377-84, 1994.

163. Tanghe KA et al. Triiodothyronine treatment attenuates the inductionof hepatic glycine N-methyltransferase by retinoic acid and elevates plasmahomocysteine concentrations in rats. J Nutr. 134, 11:2913-8, 2004. www.nutrition.org

164. Jung CH et al. Thyroid dysfunction and their relation tocardiovascular risk factors such as lipid profile, hsCRP, and waist hip ratio inKorea. Korean J Intern Med. 18, 3:146-53, 2003.

165. Makino M et al. Effect of eicosapentaenoic acid ethyl ester onhypothyroid function. J Endocrinol. 171, 2:259-65, 2001.

166. Herrick AL et al. Micronutrient antioxidant status in patients withprimary Raynaud's phenomenon and systemic sclerosis. J Rheumatol. 21,8:1477-83, 1994. www.jrheum.com

167. Simonini G et al. Emerging potentials for an antioxidant therapy as anew approach to the treatment of systemic sclerosis. Toxicology. 155,1-3:1-15, 2000. www.elsevier.com/inca/publications/store/5/0/5/5/1/8

168. Mizutani H et al. Topical tocoretinate improved hypertrophic scar,skin sclerosis in systemic sclerosis and morphea. J Dermatol. 26,1:11-7, 1999.

169. Ikeda T et al. The Vitamin A derivative etretinate improves skinsclerosis in patients with systemic sclerosis. J Dermatol Sci. 34,1:62-6, 2004.

170. Svenson K et al. Abnormal calcium, magnesium and zinc stores inperipheral blood cells from patients with inflammatory connective tissuedisease. Acta Pharmacol Toxicol , Copenh). 59, 7:386-91, 1986.

171. Tajima S et al. Inhibition of collagen hydroxylation by lithospermicacid magnesium salt, a novel compound isolated from Salviae miltiorrhizae Radix.Biochim Biophys Acta. 1200, 1:79-83, 1994. www.elsevier.nl/locate/bba

172. Elst EF et al. Treatment of linear scleroderma with oral1,25-dihydroxyvitamin D3 , calcitriol) in seven children. Pediatr Dermatol.16, 1:53-8, 1999.

173. Sheng FY et al. Inhibition of collagen production by traditionalChinese herbal medicine in scleroderma fibroblast cultures. Intern Med.33, 8:466-71, 1994.

174. Gonzalez PA et al. Andrographolide interferes with T cell activationand reduces experimental autoimmune encephalomyelitis in the mouse. JPharmacol Exp Ther. 312, 1:366-72, 2005.

175. Roy S et al. Human Genome Screen to Identify the Genetic Basis of theAnti-inflammatory Effects of Boswellia in Microvascular Endothelial Cells. DNACell Biol. 24, 4:244-55, 2005.